SHORT COMMUNICATION
Development of hammerhead ribozymes targeting miR-21
Publication date: 2015-12-21
BioTechnologia 2014;95(4):267-271
ABSTRACT
The object of the invention are hammerhead ribozymes directed against the sequence of miR-21 and /or miR-21 precursors, having the ability to specifically cleave miR-21 and /or miR- 21 precursors, and wherein they have acatalytic core with a sequence as shown in SEQ ID No 1. The invention also relates to a composition comprising such ribozymes, a therapeutic agent comprising them, a use of such ribozymes and a method of selective cleavage of miR-21 and /or 1 miR-21 precursors employing such ribozymes.
REFERENCES (8)
1.
Campbell J.M., Bacon T.A., Wickstrom E. (1990) Oligodeoxynucleotide phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophys. Meth. 20: 259-267.
2.
Ferre-D’Amare A.R., Scott W.G. (2010) Small self-cleaving ribozymes. Cold Spring Harb. Perspect. Biol. 2: a003574.
3.
Gumireddy K., Young D.D., Xiong X., Hogenesch J.B., Huang Q., Deiters A. (2008) Small-molecule inhibitors of microRNA miR-21 function. Angew. Chem. Int. Ed. Engl. 47:7482-7484.
4.
Kurreck J. (2003) Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270: 1628-1644.
5.
Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Eng. J. Med. 352: 987-996.
6.
Sun L.Q., Cairns M.J., Saravolac E.G., Baker A. et al. (2000) Catalytic nucleic acids: form lab to applications. Pharmacol. Rev. 52: 325-347.
7.
Suryawanshi H., Scaria V., Maiti S. (2010) Modulation of microRNA function by synthetic ribozymes. Mol. Biosyst. 6: 1807-1809.
8.
Westphal M., Hilt D.C., Bortey E., Delavault P., Olivares R., Warnke P.C., Whittle I.R., Jaakelamen J., Ram Z. (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncol 5: 79-88.
| eISSN: | 2353-9461 |
| ISSN: | 0860-7796 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
